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Abstract
Background: Sulfonylureas, such as glibenclamide, are antidiabetic drugs that stimulate 
beta-cell insulin secretion by binding to the sulfonylureas receptors (SURs) of adenosine 
triphosphate-sensitive potassium channels (KATP). Glibenclamide may be also cardiotoxic, 
this effect being ascribed to interference with the protective function of cardiac KATP channels 
for which glibenclamide has high affinity. Prompted by recent evidence that glibenclamide 
impairs energy metabolism of renal cells, we investigated whether this drug also affects the 
metabolism of cardiac cells. Methods: The cardiomyoblast cell line H9c2 was treated for 24 h 
with glibenclamide or metformin, a known inhibitor of the mitochondrial respiratory chain. Cell 
viability was evaluated by sulforodhamine B assay. ATP and AMP were measured according to 
the enzyme coupling method and oxygen consumption by using an amperometric electrode, 
while Fo-F1 ATP synthase activity assay was evaluated by chemiluminescent method. Protein 
expression was measured by western blot. Results: Glibenclamide deregulated energy balance 
of H9c2 cardiomyoblasts in a way similar to that of metformin. It inhibited mitochondrial 
complexes I, II and III with ensuing impairment of oxygen consumption and ATP synthase 
activity, ATP depletion and increased AMPK phosphorylation. Furthermore, glibenclamide 
disrupted mitochondrial subcellular organization. The perturbation of mitochondrial energy 
balance was associated with enhanced anaerobic glycolysis, with increased activity of 
phosphofructo kinase, pyruvate kinase and lactic dehydrogenase. Interestingly, some additive 
effects of glibenclamide and metformin were observed. Conclusions: Glibenclamide deeply 
alters cell metabolism in cardiac cells by impairing mitochondrial organization and function. 
This may further explain the risk of cardiovascular events associated with the use of this drug, 
alone or in combination with metformin.
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Introduction
Concern exists about the cardiovascular safety of the old – yet still widely prescribed 
- class of antidiabetic drugs, sulfonylureas [1]. Among the sulfonylureas currently used in 
clinical practice, glibenclamide in particular has been associated with cardiovascular events, 
including acute myocardial infarction, and mortality [2, 3], consistent with data showing 
that glibenclamide may have cardiotoxic effects [4]. By contrast, other sulfonylureas, such 
as gliclazide, seem to be safer in both epidemiological studies [3] and experimental models 
[4]. Interestingly, further increased cardiovascular risk has been reported for glibenclamide 
when it is associated with metformin [2], overriding the favourable effects on cardiovascular 
system [5].
In pancreatic beta cells, sulfonylureas act by binding to and closing ATP-sensitive 
potassium channels (KATP), the result being an increase in intracellular K+ ions, triggering 
of membrane depolarization, opening of voltage-dependent Ca2+ channels, intracellular Ca2+ 
influx and insulin secretion [6].
Cardiac toxicity of sulfonylureas has been related to the closure of specific KATP channels 
expressed in the heart [7]. Besides KATP channels, sulfonylureas also inhibit chloride and 
calcium channels inducing complex ionic events [8, 9], which regulate cell membrane 
potential during oxidative stress and ischemic preconditioning. The difference in the 
profile of cardiovascular activity among glibenclamide and other sulfonylureas may, at least 
in part, depend on differences in the affinity for the KATP channels isoforms expressed by 
cardiomyocytes.
KATP channels are expressed in both plasma and mitochondrial membranes. Recently, 
it has been shown that glibenclamide binds to the inner mitochondria membrane of 
renal tubular cells causing depletion of intracellular ATP [10]. Based on this finding, we 
hypothesized that glibenclamide could also alter mitochondrial function and ATP production 
in cardiac cells.
We compared the effects of glibenclamide and metformin (which is known to 
inhibit mitochondrial respiration and ATP synthesis) on cellular energy balance in the 
cardiomyoblast cell line H9c2. We found that glibenclamide, similar to metformin, disrupts 
mitochondrial reticulum organization, impairs mitochondrial oxidative phosphorylation, 
decreases ATP concentration, and activate phosphofructo-kinase (PFK), pyruvate kinase 
(PK) and lactic dehydrogenase (LDH), key enzymes of the anaerobic glycolytic pathway.
Materials and Methods
Reagents
Metformin, glibenclamide and gliclazide were provided by Sigma-Aldrich (St. Louis, MO, USA).
Cell Culture
H9c2 cells (RRID: CVCL_286) were obtained from ATCC and cultured in low glucose Dulbecco’s 
modified Eagle’s medium supplemented with 2 mM glutamine, 10% Fetal Bovine Serum (FBS), 100 U/ml 
penicillin, and 100 mg/ml streptomycin sulphate at 37°C in 5% CO2 as previously described [11].
AMP/ATP Ratio Assay
Cells were washed twice with PBS, lysed with 2.5% PCA and sonicated in ice three times for 10 seconds. 
After centrifugation, supernatants containing PCA were collected and neutralized with K2CO3.  ATP and AMP 
were measured according to the enzyme coupling method, following NADP/NADH reduction/oxidation at 
340 nm; 20 µg of total protein were used for both assays. For ATP quantification assay, the medium contained 
100 mM Tris-HCl pH 7.4, 5 mM MgCl2, 50 mM glucose, and 0.2 mM NADP. The assay started after the addition 
of 4 µg of purified hexokinase plus glucose-6-phosphate dehydrogenase. AMP concentration was assayed 
using the following medium: 100 mM Tris-HCl pH 7.4, 5 mM MgCl2, 10 mM phosphoenolpyruvate, 0.15 mM 
NADH, and 0.2 mM ATP. The assay started after the addition of 4µg of purified pyruvate kinase plus lactate 
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Sulforodhamine B assay.
5x105 H9C2 cells were plated in 96 mm Petri dishes in regular medium. 24 h later, the cell medium was 
removed, cells were washed twice with PBS and were incubated either in regular medium or in starvation 
medium. 24 h later cells were treated or not with metformin, glibenclamide or gliclazide. 24 hours later, cell 
medium was removed and culture plates were fixed with cold 3% trichloroacetic acid at 4°C for 30 minutes, 
washed with cold water and dried overnight. Finally, the plates were stained with 0.4% sulforodhamine B 
(SRB) in 1% acetic acid, washed four times with 1% acetic acid to remove unbound dye, dried overnight 
and solubilized with Tris base 10 mM in 200 ul. Absorbance measurements at 560nm were made using a 
microplate reader.
Oxygen consumption measurements
Oxygen consumption was measured at 37°C in a closed chamber, using an amperometric electrode 
(Unisense Microrespiration, Unisense A/S, Denmark). Cells were permeabilized with 0.03mg/ml digitonin 
for 1 min, centrifuged for 9 min at 1000 rpm and resuspended in the appropriate buffer. The same solution 
was used in the oxymetric measurements. For each experiment, 200, 000 cells were used. Ten mM pyruvate 
plus 5 mM malate were added to stimulate the pathway composed by complexes I, III and IV, while 20 
mM succinate was added to stimulate the pathway formed by complexes II, III and IV. To observe the ADP-
stimulated respiration rates, 0.08 mM ADP was added after pyruvate and malate and succinate addition. The 
respiratory rates were expressed as nmol O2/min/106 cells [12, 13].
Fo-F1 ATP synthase activity assay.
To evaluate the Fo-F1 ATP synthase activity, 200, 000 H9c2 cells were incubated for 10 min at 37°C in 
a medium containing: 10 mM Tris-HCl pH 7.4, 100 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 2.5 mM EDTA, 5 mM 
MgCl2, 0.6 mM ouabain, and 25 mg/ml ampicillin. Afterward, ATP synthesis was induced by the addition of 
10 mM pyruvate plus 5 mM malate or 20 mM succinate, to stimulate the pathways composed by complexes I, 
III and IV pathway or complexes II, III and IV, respectively. To start the reaction 0.08 mM ADP was added. The 
reaction was monitored for two minutes, every 30 sec, in a luminometer (GloMax® 20/20n Luminometer, 
Promega Italia, Milano, Italy), by the luciferin/luciferase chemiluminescent method, with ATP standard 
solutions between 10-8 and 10-5 M (luciferin/luciferase ATP bioluminescence assay kit CLSII, Roche, Basel, 
Switzerland). Data were expressed as nmol ATP produced/min/106 cells [14].
The oxidative phosphorylation efficiency (P/O ratio) was calculated as the ratio between the 
concentration of produced ATP and the amount of consumed oxygen in the presence of respiring substrates 
and ADP. When oxygen consumption is completed devoted to energy production, the P/O ratio is around 2.5 
and 1.5 after pyruvate + malate or succinate addition, respectively [15].
Respiring Complexes assays
The activity assay of the four redox complexes was measured on 50 µg of total protein homogenate 
[16]. Complex I (NADH-ubiquinone oxidoreductase) was assayed following the reduction of ferricyanide 
at 420 nm. Complex II (Succinic dehydrogenase) activity was measured at 600 nm, in 2 mM EDTA, 0.2 mM 
ATP, 20 mM succinate, 0.5 mM cyanide, 80 µM dicloroindophenol (DCIP), 50 µM decylubiquinone, 40 µM 
antimycin A, 10 µM rotenone and 10 mM phosphate buffer, pH 7.2.  To measure complex III (Cytochrome 
c reductase) activity was followed the reduction of oxidized Cytochrome c at 550 nm, in the presence of 
0.7 mM NADH, to provide the electrons, trough Complex I activity, necessary for cytochrome c reduction. 
Complex IV (Cytochrome c oxidase) was assayed following the oxidation of ascorbate-reduced Cytochrome 
c at 550 nm.
Western Blotting Analysis
H9c2 cell extracts were resolved by SDS-PAGE and transferred to a nitrocellulose membrane as 
previously described [17]. Membranes were incubated overnight at 4 °C and probed with the following 
antibodies: anti pAMPK and AMPK purchased from Cell Signaling Technologies (Boston, MA), anti ND1 and 
anti ATP synthase (ATP5B)  purchases from Sigma (St. Louis, USA) and  anti actin purchased from Abcam 
(Cambridge, UK). Primary antibodies were detected using a goat anti-mouse or goat anti-rabbit IgG HRP 
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Evaluation of glycolysis.
The activities of PFK, PK and LDH were measured at room temperature on 20 µg of preterm or term UC-
MSC total protein. Enzymatic activity was expressed as mU/mg of total protein (nmol/min/mg of protein). 
NADH molar extinction coefficient was considered 0.622 mM-1 cm-1, at 340 nm. The reaction mixtures used 
for the determination of each enzyme activity were the following [18]:
PFK (EC 2.7.1.11): 100 mM Tris-HCl pH 7.4, 2 mM MgCl2, 5 Mm KCl, 2 mM fructose 6-phosphate, 1 mM 
ATP, 0.5 mM phosphoenolpyruvate, 0.2 mM NADH, and 2 IU/ml of PK and LDH.
PK (EC 2.7.1.40): 100 mM Tris-HCl pH 7.6, 2.5 mM MgCl2, 10 mM KCl, 0.6 mM phosphoenolpyruvate, 
0.2 mM NADH, 5 mM ADP, and 1 IU/ml of LDH.
LDH (EC 1.1.1.27): 100 mM Tris-HCl pH 7.4, 0.2 mM NADH, and 5 mM pyruvate.
Immunoflurescence
H9c2 cells were plated on glass coverslips and treated for  24h with metformin (2, 5 mM MTF), 
glibenclamide (100 μGLB), or both molecules (2, 5 mM MTF/100 μM GLB). Cells were  treated using 
mitotracker 5 μM, incubated at 37°C for 10 minutes in the dark, washed twice and fixed with 4% PFA. 
Images were acquired on a Leica TCS SP confocal laser scanning microscope, equipped with 476, 488, 543 
and 633 excitation lines with a 60x Plan Apo oil objective. The MitoTraker Red signal was then analyzed, 
after background subtraction, using ImageJ 1, 46 software (Wayne Rasband, National Institutes of Health, 
Bethesda, MD, USA) using a semi-manual method based on the delimitation of the cells.  We measured 
mitochondrial morphological characteristics for each cells, as previously described [19]. Average circularity 
[19] was used as an indicator for mitochondrial morphological changes.
JC-1 analysis
H9c2 cells were plated in 6-well plates and treated 24h with metformin (2, 5 mM MTF), glibenclamide 
(100 μM GLB), or both molecules (2, 5 mM MTF/100 μM GLB). At the end of treatment, cells were incubated 
with (1: 200) JC-1 dye (Thermo Fisher Scientific, Waltham, MA) for 15 min at 37°C in a 5% CO2 incubator. 
Cells were washed  and subjected to FACS analysis. The ratios of red-to-green fluorescence emissions were 
quantitated to further estimate the extent of mitochondrial membrane damage.
Statistical Analysis
All experiments were performed at least 3 times. Data are presented as mean ± SEM. Comparisons were 
drawn by ANOVA (SPSS 16.0; SPSS, Chicago, IL) and P values <0.05 were considered statistically significant.
Results
To investigate whether glibenclamide could affect cell metabolism, H9c2 cardiomyoblasts 
were treated for 24 hr with different doses of glibenclamide, gliclazide, or metformin. 
Glibenclamide caused a dose-dependent increase of the AMP/ATP ratio, indicating an 
impairment of the energy balance (Fig. 1 panel A). As expected, gliclazide did not modify the 
AMP/ATP ratio in H9c2 cells (Fig. 1 panel B). Metformin also increased the AMP/ATP ratio 
in this cellular model (Fig. 1 panel C). As shown in Fig. 1 panel D, glibenclamide treatment 
reduced cell viability in a dose-dependent manner, while gliclazide (Fig. 1 panel D) and 
metformin (Fig. 1 panel E) did not alter the vitality of H9C2.
Since cells respond to ATP depletion by activating AMPK, we analysed the effect of 
glibenclamide on AMPK phosphorylation by western blot. Again similar to metformin, 
and consistent with the increase in the AMP/ATP ratio, glibenclamide increased AMPK 
phosphorylation (Fig. 2).
The main source of ATP is oxidative phosphorylation, which occurs in mitochondria. 
Therefore, glibenclamide and metformin effects on mitochondrial oxygen consumption and 
ATP synthesis were determined. Oxygen consumption and ATP synthase activity decreased 
in the presence of glibenclamide in a dose dependent manner, after adding both pyruvate 
plus malate, a mix of substrates activating the complexes I, III and IV pathways, and succinate, 
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tion and ATP syn-
thase activity only 
after the addi-
tion of pyruvate 
plus malate, con-
firming that com-
plex I is the main 
metformin target 
[20] (Fig. 3 Pan-
els  C, D). Gliben-
clamide, as well 
as metformin, did 
not display any 
uncoupling effect. 
In fact, P/O ratios 
ranged from 2.5 to 
1.5 following the addition of pyruvate plus malate or succinate, respectively (Table 1).
To identify the respiratory chain target of glibenclamide, we assayed the activity of each 
mitochondrial respiring complex. Glibenclamide inhibited the activity of complexes I, II and 
III, but not of complex IV (Fig. 4 panels A, B, C, D). It is important to note that the inhibition 
Fig. 1. Glibenclamide 
increases AMP/ATP 
ratio and induces 
toxicity in H9C2 cells. 
H9C2  cells were 
treated for 24 hr with 
different doses of (A) 
glibenclamide (GLB), 
(B) gliclazide (GLZ) 
and (C) metformin 
(MTF);  ATP and 
AMP concentrations 
were determined 
by enzymatic assay, 
and AMP/ATP ratio 
was then calculat-
ed. H9C2 cells were 
treated with increas-
ing doses of gliben-
clamide and  gliclazi-
de (D) and metformin 
(E), 24h later cells 
were fixed, stained 
and viability was 
detected by 96 SRB 
assay. Bars indicate 
mean ± SE. (* p<0.05; 
**p<0.01;***<p0.001; 
GraphPad Software).
Fig. 2. Glibenclamide in-
creases AMPK phosphory-
lation in H9c2 cells. H9c2 
cells were treated for 24 hr 
with metformin (MTF) and 
glibenclamide (GLB) at the 
indicated concentrations 
and levels of p-AMPK and 
total AMPK were examined 
by immunoblotting. Rep-
resentative western blots 
and densitometric analysis 
of the p-AMPK signal nor-
malized against the one of 
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Fig. 3. Oxygen consumption and ATP synthesis in H9c2 cells treated with glibenclamide and metformin. 
H9c2 cells were treated for 24 hr with metformin (MTF) and glibenclamide (GLB) at the indicated concen-
trations. Oxygen consumption (A,C) and ATP synthesis via Fo-F1 ATP synthase (B,D) were evaluated at the 
end of the incubation after adding pyruvate + malate (dark grey columns) or succinate (light grey columns). 
* p<0.05, ** p<0.01 and *** p<0.005 vs. control.
Table 1. Effect of glibenclamide or metformin on P/O 
ratio. Data are the P/O ratio of H9C2, as the meas-
ure of the efficiency of OXPHOS metabolism, in the 
presence of several concentrations of glibenclamide 
or metformin. Data are expressed as mean ±S.D. and 
represent at least three experiments
 
Table 1: Effect of Glibenclamide or Metformin on P/O ratio. Data reports the P/O ratio of H9C2, as the measure of 
the efficiency of OXPHOS metabolis , in the presence of several concentrations of glibenclamide or metformin. 













   P/O (Pyr/Mal) 
P/O 
(Succinate) 
CTR 2.44 ± 0.01 1.50 ± 0.04  CTR  2.45 ± 0.03 1.49 ± 0.02 
1 2.49 ± 0.03 1.48 ± 0.03  0.5  2.50 ± 0.02 1.47 ± 0.02 
10 2.53 ± 0.01 1.49 ± 0.02  0.01 2.49 ± 0.06 1.51 ± 0.04 
50 2.57 ± 0.08 1.53 ± 0.05  0.5  2.57 ± 0.13 1.47 ± 0.01 
100 2.33 ± 0.17 1.46 ± 0.02  1  2.43 ± 0.00 1.46 ± 0.05 








CTR 2.45 ± 0.03 1.49 ± 0.02 
0.5 2.50 ± 0.02 1.47 ± 0.02 
0.01 2.49 ± 0.06 1.51 ± 0.04 
0.5 2.57 ± 0.13 1.47 ± 0.01 
1 2.43 ± 0.00 1.46 ± 0.05 














Glibenclamide (uM)  Metformin (mM) 
Fig. 4. Effect of glibenclamide on the mitochon-
drial respiring complexes. H9c2 cells were treat-
ed for 24 hr with 250 μM glibenclamide (GLB) 
and complex I (A), complex II (B), complex III 
(C)  and complex IV (D) activity was measured as 
indicated in Materials and Methods . ** p<0.01 vs. 
control.
chain complexes in H9c2 cells.
Then, we tested the effect of combined treatment with glibenclamide and metformin 
on H9c2 cells. Compared to glibenclamide alone, the addition of 2.5 mM metformin to in-
creasing concentrations of glibenclamide (50-250 μM) significantly increased the  AMP/ATP 
of complex III may be related with the inhib-
ition of complex I, as this latter represents 
a functional component of the complex III 
assay (see Materials and Methods section). 
Thus, despite a similar final effect on oxida-
tive phosphorylation, metformin and gliben-
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Fig. 5. Combined effect 
of glibenclamide and 
metformin on energet-
ic status and oxidative 
phosphorylation of 
H9c2 cardiomyoblasts. 
H9c2 cells were treat-
ed for 24 hr with 2.5 
mM metformin (MTF), 





ing treatments (A) the 
AMP/ATP ratio, (B) 
oxygen consumption, 
and (C) ATP synthesis 
were evaluated. (D) 
H9c2 cells were treat-
ed for 24 hr with met-
formin (MTF), gliben-
clamide (GLB) and met-
formin/glibenclamide 
association using the 
indicated concentra-
tions. β subunit of ATP 
synthase and ND1 (a 




western blots and 
densitometric analysis 
of the signals normal-
ized against the one 
of total beta-actin are 
shown.  ** p<0.01 *** 
p<0.005 vs. control.
ratio, decreased oxygen consumption and ATP synthase activity (Fig. 5, Panels A, B, C). To 
determine the expression of respiratory chain proteins we performed western blot analysis 
of ND1, a subunit of Complex I and of ATP synthase ß subunit. Glibenclamide and metformin 
decreased the expression of both proteins, solely and in association (Fig. 5, Panel D) showing 
an additive effect.
Respiratory chain function may be also influenced by alterations of mitochondrial 
distribution in the cell. Therefore, we evaluated the organization of the mitochondrial reticulum 
by confocal analysis in the presence of glibenclamide, metformin or their combination after 
24h of treatment. After glibenclamide or metformin treatment, the mitochondrial reticulum 
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Fig. 7. Enhancement of the glycolytic 
flux in H9c2 treated with glibenclamide 
and metformin. H9c2 cells were treated 
for 24 hr with 2.5 mM metformin (MTF), 
increasing doses of glibenclamide (GLB) 
(0uM-250uM) and their combination. 
(A) The activity of  phosphofructokinase 
(PFK), (B) pyruvate kinase (PK) and (C) 
lactate dehydrogenase (LDH) was then 
assessed.  * p<0.05; ** p<0.01; *** p<0.005 
and **** p<0.001;  vs corresponding 
control.
punctated distribution following 
combined treatment compared to 
the single treatments, indicating a 
synergistic effect of glibenclamide 
and metformin (Fig. 6 panel A). 
Moreover, to deeply characterize 
mitochondrial asset following 
treatment, mitochondrial network 
integrity was determined analysing 
circularity parameter (Fig. 6 
panel B). H9C2 treated cells were 
labelled with mito-traker dye and 
subjected to confocal microscopy 
analysis. As shown in Fig. 6 panel C, 
glibenclamide, metformin and their 
association significantly reduced 
mitochondrial interconnectivity 
and elongation compared to the 
control.
We measured also 
mitochondrial membrane potential, 
which was expressed as the 
absolute red/green ratio. As expected, metformin induced mitochondrial depolarization. 
Interestingly also glibenclamide caused a significant reduction in the red/green fluorescence 
Fig. 6.  Mitochondrial reticulum morphology 
after treatment with glibenclamide and 
metformin. (A) Representative confocal 
images showing the morphology and 
distribution of the mitochondrial reticulum 
in H9c2 cardiomyoblasts after 24h 
treatment with metformin (2,5 mM MTF), 
glibenclamide (100 μM GLB), or both 
molecules (2,5 mM MTF/100 μM GLB). Scale 
bar 20µm. (B) The bar diagram showed 
mitochondrial morphological changes 
analyzed by the means of circularity. (C) The 
bar diagram shows the ratio of JC-1 red to 
green fluorescence under each treatment 
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ratio indicating a drop in mitochondrial membrane potential (Fig. 6 panel C). The association 
of the molecules elicited a decrease in membrane potential stronger than the one triggered 
by either drug alone.
Finally, we examined glycolysis in H9c2 cells by measuring the activity of the PKF, PK and 
LDH, three key enzymes of the anaerobic glycolysis flux. As presented in Fig. 7, the activity 
of PKF, PK and LDH increased in the presence of metformin as well as of glibenclamide. 
Interestingly, we observed a further increment with the combination of the two molecules.
Discussion
This study shows that glibenclamide affects energy metabolism of H9c2 cardiomyoblasts, 
an established cell model for the evaluation of drug cardiotoxicity [11, 21]. Treatment of 
H9c2 cells with glibenclamide leads to a profound depletion of ATP, secondary to altered 
mitochondrial organization and oxidative phosphorylation. Overall, this metabolic 
perturbation is similar to the one induced by metformin, a well-known inhibitor of complex 
I of the respiratory chain [22].
H9c2 cardiomyoblasts express the SUR2A/Kir6.1 and SUR2A/Kir6.2 KATP channels 
isoforms [5]. To understand whether metabolic impairment by glibenclamide was KATP 
channels dependent, we also exposed the cells to equimolar concentrations of gliclazide, a 
second-generation sulfonylurea like glibenclamide, but with no affinity for the KATP channels 
subtypes of H9c2 cells [7]. ATP levels were not modified by gliclazide, providing indirect 
evidence that metabolic toxicity of glibenclamide occurs via binding to KATP channels. 
Metformin and glibenclamide are very different molecules with different mechanism of 
action. Similarly to metformin [23, 24] glibenclamide increases AMPK phosphorylation and 
mitochondrial dysfunction.
It has already been demonstrated that mitochondria express SUR and that glibenclamide 
can inhibit potassium fluxes in mitochondria of renal cells [10]. The functional characterization 
of a sulfonylurea receptor SUR2 splice variant, in fact, has been reported also in cardiac 
mitochondria [25]. H9c2 cells express SUR2A/Kir6.1 and SUR2A/Kir6.2 [5], which are 
bound by glibenclamide but not gliclazide [7]. This result suggests that binding to SUR2A/
Kir6.1 and SUR2A/Kir6.2 is necessary for glibenclamide-mediated ATP depletion. It remains 
to be determined whether inhibition of the respiratory chain by glibenclamide is directly 
mediated by mitochondrial KATP channels or whether it is the consequence of intracellular 
events triggered by glibenclamide after binding to cytoplasmic and/or mitochondrial KATP 
channels [26]. Mitochondria reticulum integrity is necessary to maintain cell energy balance. 
We found that glibenclamide disrupts mitochondria reticulum integrity similarly to inhibitors 
of the respiratory chain such as piericidin and myxothiazol that cause fission of mitochondria 
[27]. Our data show that metformin also causes mitochondria to switch from an elongated, 
tubular shape to a punctate one. This perturbation in mitochondrial organization could be 
related to the energy balance dysfunction observed with both molecules.
Metformin directly inhibits complex I [28, 29] while glibenclamide inhibits complexes 
I-II-III. These findings suggest that glibenclamide and metformin combined treatment 
could potentiate each other respiratory chain destabilization. Here metformin but also 
glibenclamide reduced the expression of ND1 and ATP synthase β subunit. This result could 
be related to the impairment of oxidative phosphorylation. Since ND1 and ATP synthase β 
subunit are codified by two different subcellular compartments, respectively mitochondria 
and nucleus, a transcriptional mechanism is unlikely. An alternative explanation could be 
that glibenclamide binds to the mitochondria inner membrane.
Metformin action on mitochondria is well established. Metformin decreases the 
functionality of complex I [20]. The inhibition of complex I could be a generic effect 
resulting from molecular changes occurring in the inner mitochondrial membrane following 
the binding of metformin to phospholipids [22, 30]. Interestingly it has been shown that 
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interfere with the conformations of important mitochondrial proteins, including respiratory 
chain complexes.
Clinical trials and registries have consistently shown that metformin does not increase 
cardiovascular morbidity and mortality of diabetic patients; in fact, a favourable effect of 
metformin on diabetes-related cardiovascular risk has been reported [5]. Consistently, most 
experimental studies have demonstrated that metformin prevents ischemic cardiac damage, 
this protection being ascribed to various pathways, not necessarily downstream of the 
reduction in complex I activity, such as activation of AMPK and phosphoinositide 3-kinase/
AKT, enhanced intramyocardial availability of adenosine, blunting of oxidative stress, and 
inhibition of mitochondrial permeability transition pore opening [24, 31]. By contrast, 
therapy with glibenclamide has been associated with negative cardiovascular outcomes in 
epidemiological analysis [2, 3] and glibenclamide has been shown to worsen ischemic injury 
of cardiomyocytes in cell and animal models [31]. This toxicity has been primarily related 
to the closure of KATP channels [7]. Here we describe that glibenclamide also elicits a drop 
in ATP concentrations in cardiac cells like metformin. Nonetheless, glibenclamide, but not 
metformin decreased H9c2 cell viability in our experiments. Further work is needed to better 
understand mechanisms of this difference and to dissect the actions of glibenclamide and 
metformin on H9c2 cells. The combined effect of glibenclamide and metformin will deserve 
particular attention, as clinical investigations pointed to an increased cardiovascular risk 
when diabetic patients are given both drugs [2].
In our model, gliclazide did not modify the AMP/ATP ratio. Even though this finding 
cannot be extrapolated to cell types other than the H9c2 line, it is in good agreement with 
the literature suggesting that gliclazide is safer than glibenclamide as far as cardiovascular 
outcomes are concerned and, thereby, represents a valid therapeutic option for type 2 
diabetes [32].
Conclusion
The experiments presented here add new data on the effects of glibenclamide on cardiac 
cells, showing that this drug interferes with mitochondrial organization and inhibits oxidative 
phosphorylation. This may further explain the risk of cardiovascular events associated with 
glibenclamide use. Furthermore, changes in energy metabolism should be taken into account 
by future investigations addressing the effects of glibenclamide on cardiac cells or the whole 
heart.
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